$22.97
-1.86 (-7.49%)
Open$26.22
Previous Close$24.83
Day High$26.60
Day Low$22.42
52W High$70.88
52W Low$8.73
Volume—
Avg Volume1.31M
Market Cap1.75B
P/E Ratio—
EPS$-4.05
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-23.8% upside
Current
$22.97
$22.97
Target
$17.51
$17.51
$11.65
$17.51 avg
$27.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 19.42M | 36.46M | 366.27M |
| Net Income | -240,021,669 | -405,518,119 | 43.81M |
| Profit Margin | -1,236.0% | -1,174.2% | 12.0% |
| EBITDA | -205,789,343 | -366,998,077 | 53.48M |
| Free Cash Flow | — | — | 19.66M |
| Rev Growth | -46.7% | -46.7% | -4.9% |
| Debt/Equity | 2.63 | 2.63 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |